Introduction
The use of a single analgesic to treat moderate to severe postoperative pain has proved inadequate to ensure optimal analgesia. Multimodal analgesia is currently recommended for effective postoperative pain control. 1 Principles of a multimodal strategy include control of postoperative pain of the patient to allow early mobilization, early enteral nutrition, education, and attenuation of the perioperative stress response through the use of a combination of analgesic agents. 1, 2 A multimodal strategy to control postoperative pathophysiology and facilitate rehabilitation results in accelerated recovery and decreased length of hospitalization. 3 Patients undergoing major abdominal procedures and who participate 5 Presented in part at the XXIII Annual ESRA Congress, Greece, 2004. in a multimodal strategy have a reduction in hormonal and metabolic stress, preservation of total-body protein, shorter times to extubation, lower pain scores, earlier return of bowel function, and earlier fulfillment of intensive care unit discharge criteria. 2 The multimodal approach may even reduce the length of hospitalization for patients undergoing colon resection from a median of 6-10 days to 2 days. 4 This approach may decrease perioperative morbidity, and improve patient satisfaction without compromising safety. Preemptive analgesia is one of the components for multimodal strategy. The concept of preemptive analgesia consists of an antinociceptive treatment that prevents central neural sensitization that amplifies postoperative pain. This implies that the treatment has been established when the noxious stimulus starts.
2 Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly administered as adjuvants during the preoperative period because of their ability to improve the control of postoperative pain while reducing the need for opioid analgesics. 1 However, the possible preemptive analgesic effect of NSAIDs is currently being debated.
Lornoxicam is a relatively new thienothiazine derivative of the oxicam class of NSAIDs. In animal studies, lornoxicam has demonstrated cylo-oxygenase inhibitory activity approximately 100 times more powerful than that of tenoxicam, along with analgesic activity approximately 10 times greater than that of either tenoxicam or piroxicam. 5 Additionally, and in contrast to other oxicams, lornoxicam has a short plasma half-life of approximately 4-6 h. This may translate into a better tolerability profile for lornoxicam, since NSAIDs with long plasma half-lives have been associated with a higher incidence of adverse effects.
5
In the present study, we tried to assess the effect of intravenous lornoxicam administered before incision or after incision on tramadol consumption in the postoperative period.
Methods
The study protocol was approved by the hospital Ethics Committee, and a written informed consent was obtained from all patients before the study. The study included 60 adult patients undergoing major abdominal surgery (upper or upper and lower medial laparotomy) and treated postoperatively in the surgical intensive care unit. Exclusion criteria were as follows: preoperative use of analgesics, allergy to NSAIDs, history of peptic ulcer disease, coagulopathy, or renal dysfunction. Sixty patients were randomly assigned to three groups. On arrival at the preanesthetic room, standard monitoring equipment consisting of electrocardiography, noninvasive blood pressure monitoring, and pulse oximetry was installed. Laboratories, North Chicago, IL) and the visual analog scale (VAS; 0 ¼ ''no pain'' and 10 ¼ ''worst pain imaginable'') for pain. A standardized general anesthetic was used. Induction was achieved with 10 mg/kg atropine, 1 mg/kg remifentanil, 2 mg/kg propofol. Atracurium (0.5 mg/kg) was given to facilitate orotracheal intubation. Maintenance of anesthesia consisted of desflurane 4-6% (end-tidal) and 60% nitrous oxide in oxygen. Remifentanil infusion was started at an initial rate of 0.5 mg/ kg/min. After intubation, remifentanil infusion rate was reduced by 50%. At the completion of skin closure, muscle relaxation was reversed and patients extubated.
After tracheal extubation, patients were transferred to the PACU. Postoperative pain was assessed using a visual analog scale. Postoperative analgesia was provided by i.v. PCA tramadol (Salutas Pharma GmbH, Germany). Patients were connected to the PCA-device on arrival in the PACU. The PCA solution contained tramadol 3 mg/mL. The administration variables were as follows: initial dose, 50 mg; demand dose, 20 mg; lockout interval, 10 min; 4-h limit, 300 mg; and no basal infusion. Pain was assessed using VAS (at rest, on exertion) at 1 h, 2 h, 4 h, 12 h, and 24 h after surgery. Patients were given additional analgesic (lornoxicam 8 mg i.m.) when analgesia was inadequate (VAS > 3). Total and incremental tramadol consumption at these times was also recorded from the PCA-device. Patients were evaluated for the presence of adverse events such as nausea, vomiting, dizziness, drowsiness, sedation, anxiety, dyspepsia, indigestion. Nausea was evaluated using a two point scale; 0 ¼ absent, 1 ¼ positive. Metoclopramide was given in the case of vomiting or after two successive episodes of nausea. The degree of sedation was rated on a four-point scale; 0 ¼ awake, 1 ¼ drowsy, 2 ¼ asleep but rousable, 3 ¼ unrousable. All measurements were recorded by the same anesthesia resident who was blinded to the study drugs administered. At the end of the study, patient satisfaction was questioned (excellent, good, fair, poor).
The postoperative tramadol consumption was used as the main criterion for statistical analysis. We calculated that 15 patients in each group would be necessary for the assessment of a 20% decrease in tramadol consumption for treatment groups with a Type 1 error value of 0.05 and power of the study 80%. Demographic characteristics were analyzed using Student's t-test, while the VAS pain scores and PCA tramadol usage were analyzed using Fisher's exact test. The Chi-square test was used to analyse the frequency of nausea, vomiting or pruritus. Statistically testing was performed using SPSS 10.0 program for Windows (SPSS Inc., Chicago, IL), with a P value <0.05 considered statistically significant.
Results
The demographic characteristics were similar, and there were no significant differences with respect to duration of surgery ( Table 1 ).The VAS scores were significantly higher in the control group compared with the Group PRE and Group POST at 1 h, 2 h, 4 h, and 12 h after surgery (P < 0.05) ( Tables 2 and 3 ).
The VAS scores at 1 h, 2 h, 4 h, and 12 h in Group PRE were i n t e r n a t i o n a l j o u r n a l o f s u r g e r y 6 ( 2 0 0 8 ) 1 9 3 -1 9 6 lower than Group POST, but there was significant difference in VAS scores at 2 h (P > 0.05) ( Tables 2 and 3 ). Tramadol consumption in Group PRE and Group POST was lower than Group C (P < 0.05) ( Table 4 ). Although tramadol consumption was determined to be lower in Group PRE than Group POST in all measuring time, there was no significant difference in total tramadol consumption between. Adverse events observed during the study and patient satisfaction are summarized in Tables 5 and 6 . In total, 39 adverse events were reported by 26 (43.3%) patients. The most commonly reported adverse events in all three groups were vomiting and nausea. All adverse events were mild to moderate in intensity; most were transient. No severe or serious adverse events were reported. There were no significant differences in the incidence of adverse events (P > 0.05).
Discussion
The authors of studies on the preemptive analgesic effects of NSAIDs have reported contradictory results, although its clinical and experimental existence has been established. 6, 7 Lornoxicam is a NSAID that blocks constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) and consequently inhibits the production of prostaglandins and reduces the development of sensitization process. 8 The antinociceptive and anti-inflammatory action of NSAIDs may be related to the inhibition of nitric oxide synthase activation, reduced production of pro-inflammatory cytokines (through their inhibitory action on the nuclear factor NF-kB) and lipoxine activation (endogenous anti-inflammatory mediators). 10 Consequently, the multidirectional action of NSAIDs suggests that there may be a possibility of modifying the nociception process by the use of these drugs to induce preemptive analgesia in the perioperative period.
Our results demonstrate that preoperative single dose lornoxicam reduced VAS pain scores and tramadol consumption. A similar benefit has been previously demonstrated by combining NSAIDs with opioids, where the addition of these analgesics reduced the consumption of opioids. 5, [9] [10] [11] It has been demonstrated that lornoxicam improves the quality of postoperative analgesia and leads to reduced consumption of opioid analgesics. 11 Ilias and Jansen, 5 reported that preoperative administration of lornoxicam 8 mg produces equaanalgesic effect to tramadol 50 mg and is better tolerated. Nausea and vomiting have been reported in previous studies with lornoxicam. 5, 11 However, a number of other factors have been shown to contribute to these events, including the administration of anesthetic agents, surgical procedure and anesthetic techniques, hypotension, and a previous history of postoperative nausea and motion sickness. 5 Also, the administration of opioids with a PCA system can aggravate postoperative nausea and vomiting. In the present study, although nausea and vomiting were observed more frequently Data are presented as mean AE SD. There were no significant differences among the three groups. i n t e r n a t i o n a l j o u r n a l o f s u r g e r y 6 ( 2 0 0 8 ) 1 9 3 -1 9 6 in the placebo group, these differences were not statistically significant. It should be noted the preoperative administration of lornoxicam was accompanied by a lower incidence of nausea and vomiting, which was probably linked to the lower consumption of tramadol and better pain control. It is known that NSAIDs inhibit biosynthesis of thromboxane A2. The reduced production of thromboxane A2 prevents platelet aggregation and may increase blood loss during and after surgery. NSAIDs decrease platelet aggregation and increase bleeding time and thus may increase perioperative and postoperative bleeding. 12 Rogers et al. 13 found that intraoperative median blood loss in patients receiving ketorolac before laparoscopic gynaecological surgery exceeded that of patients who received it after surgery. In their study of the analgesic efficacy of diclofenac after major abdominal surgery, Hodsman et al. 14 report on two diclofenac group patients submitted to abdominoperitoneal resection of the rectum with extensive pelvic dissection. Both patients developed postoperative bleeding and required reoperation. However, studies using lornoxicam and ketoprofen have not detected problems with surgical bleeding, bleeding time, blood transfusions requirements, or postoperative bleeding. 5, 11 In our study, there was no case of excessive bleeding in the lornoxicam groups during the postoperative period, and none of the patients from either group required reoperation. Gastrointestinal complications (gastritis, ulcer perforation and bleeding, dyspepsia, indigestion) have been well described with the chronic use of NSAIDs. 15 However, the risk of serious gastrointestinal adverse effects with NSAIDs is very low after short-term perioperative use. In this study, only one patient in the lornoxicam preincisional group complained of dyspepsia.
In conclusion, lornoxicam administered preemptively appears to improve the quality of postoperative analgesia and lead to reduced consumption of tramadol postoperatively in patients undergoing major abdominal operations.
